Health Care/Hospital

Kexing Biopharm Facility Passes EU GMP Certification for Paclitaxel for Injection (Albumin Bound)

SHENZHEN, China, May 10, 2024 /PRNewswire/ -- On the evening of May 5, Kexing Biopharm (stock code: 688136) announced it had obtained a "Certificate of GMP Compliance of a Manufacturer" granted by the Norwegian Medical Products Agency in accordance with the European Medicines Agency (EMA) regulat...

2024-05-10 20:07

Nuvilab Becomes B Corp Certified

SEOUL, South Korea, May 10, 2024 /PRNewswire/ -- Nuvilab, a leading provider of food vision AI, announced its recent achievement of becoming a certified B Corp. The designation, granted by the non-profit B Lab, highlights Nuvilab's commitment to a range of sustainable practices encompassing gover...

2024-05-10 19:59

Ribobay Pharma boosts CRDMO offerings with Cytiva's first FlexFactory platform for oligonucleotides

* FlexFactory platform for oligonucleotides, an integrated solution to boost efficiency and speed of pharmaceutical manufacturing to meet market demand SHANGHAI, May 10, 2024 /PRNewswire/ -- Ribobay Pharma, a leading Chinese biopharmaceutical contract research, development, and manufacturing o...

2024-05-10 18:39 460

WestGene's mRNA Therapeutic Cancer Vaccine Receives FDA Approval

CHENGDU, China, May 10, 2024 /PRNewswire/ -- WestGene, a biotech company dedicated to mRNA technology, announces a historic milestone with the FDA IND approval of its mRNA therapeutic cancer vaccine, WGc-043. This landmark achievement marks the world's first approval of an EB virus-related mRNA ...

2024-05-10 12:16 1161

SN Bioscience Receives FDA Fast Track Designation for Small Cell Lung Cancer

SEOUL, South Korea, May 9, 2024 /PRNewswire/ -- SN Bioscience Co. Ltd. (CEO Park Young-hwan) announced on May 7 that the FDA has granted Fast Track Designation for small cell lung cancer (SCLC) for SNB-101 (API: SN-38), a new drug for polymer nanoparticle anticancer under clinical trial. SNB-101 ...

2024-05-10 12:00 807

Celltrion USA's adalimumab-aaty biosimilar to HUMIRA® now available at low wholesale acquisition cost

* Adalimumab-aaty will be priced at an 85% discount to HUMIRA® (adalimumab) * Branded and unbranded versions of Celltrion USA's adalimumab biosimilar help provide more affordable options for patients JERSEY CITY, N.J., May 9, 2024 /PRNewswire/ -- CelltrionUSA announced today that adalimumab-aa...

2024-05-10 07:41 638

FDA Clears the Individualized Nomogram for Rika Plasma Donation System

The latest innovation is anticipated to increase collection volume without increasing collection time * Rika's individualized nomogram, iNomi, can enable plasma donors to donate the right amount of plasma on any given day based on height, weight and hematocrit. * The Rika Plasma Donation Sys...

2024-05-09 20:00 668

Infinitopes' Article in Peer-Reviewed Journal Seeks to Unlock the Potential of Cancer Vaccines

Publication in Human Vaccines and Immunotherapeutics highlights progress in understanding tumour biology and vaccine technologies since the pandemic OXFORD, England, May 9, 2024 /PRNewswire/ -- Infinitopes Precision Immunomics, an integrated cancer biotech combining world leading platforms in pr...

2024-05-09 15:30 903

Formosa Pharmaceuticals Announces Licensing Agreement with Tabuk Pharmaceuticals, for Commercialization of Clobetasol Propionate Ophthalmic Suspension for the Treatment of Inflammation and Pain Following Ocular Surgery

TAIPEI, May 9, 2024 /PRNewswire/ -- Taiwan-based Formosa Pharmaceuticals ("Formosa", 6838.TWO) announced today that the company has entered into an exclusive licensing agreement with Tabuk Pharmaceuticals Manufacturing Company ("Tabuk"), for exclusive rights to the commercialization of clobetasol...

2024-05-09 15:00 1153

Front Street Re Appoints Edison Fong as Chief Executive Officer

GEORGETOWN, Cayman Islands, May 8, 2024 /PRNewswire/ -- Front Street Re  ("FSR" or the "Company"), an international Insurtech and reinsurance company that focuses on annuity, life, health, and general reinsurance solutions and is an operating subsidiary ofLexasure Fin...

2024-05-08 21:22 659

NeuShen Therapeutics Initiates First-in-Human Trial of NS-136, a Novel Selective M4 Receptor Positive Allosteric Modulator for the Treatment of Schizophrenia

SHANGHAI and LEXINGTON, Mass. , May 8, 2024 /PRNewswire/ -- NeuShen Therapeutics (the "Company"), a clinical-stage global biotechnology company dedicated to pioneering treatments for neurological and psychiatric disorders, today announced the dosing of the first healthy volunteer inAustralia in t...

2024-05-08 21:00 958

TiumBio Announces Positive Topline Data from Phase 2a Trial of Merigolix in Patients with Moderate to Severe Endometriosis-Associated Pain

* The study (NCT05138562) met its primary endpoint of change of dysmenorrhea (menstrual pain) score from baseline to 12 weeks compared to placebo across all tested doses (120 mg, 240 mg, and 320 mg)  * Merigolix is expected to emerge as a best-in-class treatment based on its excellent pain re...

2024-05-08 20:00 691

Minghui Pharmaceutical to Present the Phase I/II Study of MHB088C (B7-H3 ADC) for the Treatment of Patients with Recurrent or Metastatic Solid Tumors in Late-breaking Oral Presentation at the 2024 ASCO Annual Meeting

SHANGHAI, May 8, 2024 /PRNewswire/ -- Minghui Pharmaceutical, Inc., a late-stage clinical biopharmaceutical company focused on autoimmune diseases and oncology, will feature Dr.Lin Shen from Beijing Cancer Hospital at the upcoming ASCO Annual Meeting inChicago. Dr. Shen will present the results f...

2024-05-08 18:18 5276

Andall Biosciences Introduces 23WELL: A Breakthrough New Brand with Ovary Care Capsules (1+1) as its Stellar Debut Product

SHANGHAI, May 8, 2024 /PRNewswire/ -- Andall Biosciences Inc. (ABI), a renowned biotechnology company at the forefront of life science research and applications, has made a significant stride with the introduction of their groundbreaking new product line, 23WELL. The brand takes center stage with...

2024-05-08 18:11 729

Research Results on Jolly Good's Medical VR Will Be Presented for the First Time in the U.S. - Revealing Training VR for HALO Procedures at Large-Scale VR Seminar, SAEM2024

BROOKLINE, Mass., May 7, 2024 /PRNewswire/ -- Jolly Good US Inc. is proud to announce the groundbreaking debut of research findings on its Medical Virtual Reality (VR) platform inthe United States. This unveiling will take place at the annual meeting of the Society for Academic Emergency Medicine...

2024-05-08 02:00 1021

"Momcozy Village" Campaign Elevates Support for Mothers with Upcoming Events and Initiatives

NEW YORK, May 7, 2024 /PRNewswire/ -- As we approach Mother's Day, Momcozy , a leader in maternal and infant care, is excited to share more details about its "Momcozy Village" campaign. This initiative focuses on stren...

2024-05-07 22:30 707

FDA Grants Orphan Drug Designation to 9MW2821

SHANGHAI, May 7, 2024 /PRNewswire/ -- Mabwell (688062.SH), an innovation-driven biopharmaceutical company with entire industry chain, announced that its self-developed novel Nectin-4-targeting ADC (R&D code: 9MW2821) has been granted Orphan Drug Designation (ODD) by the U.S. Food and Drug Adminis...

2024-05-07 22:00 767

Meihua International Medical Technologies Co., Ltd. to Present at the Emerging Growth Conference on May 9, 2024

Meihua International Medical Technologies Co., Ltd. invites individual and institutional investors as well as advisors and analysts, to attend its real-time, interactive presentation at the Emerging Growth Conference. YANGZHOU, China, May 7, 2024 /PRNewswire/ -- Meihua International Medical Tech...

2024-05-07 21:08 887

Mr. Kong, Nano Labs' Chairman and CEO, Increased His Shareholding in the Company

HANGZHOU, China , May 7, 2024 /PRNewswire/ -- Nano Labs Ltd (Nasdaq: NA) ("we," the "Company" or "Nano Labs"), a leading fabless integrated circuit design company and product solution provider inChina, announced today that Mr. Jianping Kong, the Company's chairman and chief executive officer, inf...

2024-05-07 21:00 1657

GC Genome to Present New Clinical Data on Colorectal Cancer Detection at the ASCO Annual Meeting 2024

YONGIN, South Korea, May 7, 2024 /PRNewswire/ -- GC Genome Corporation, a leading diagnostics company, today announced that it will present the new clinical data of its AI-based liquid biopsy platform on colorectal cancer detection at the 2024 American Society of Clinical Oncology (ASCO) Annual ...

2024-05-07 13:27 1004
12345 ... 256